Literature DB >> 1387344

In search of specific cytotoxic T lymphocytes infiltrating or accompanying human ovarian carcinoma.

M Apiranthitou-Drogari1, C Paganin, S Bernasconi, G Losa, A Maneo, N Colombo, A Mantovani, P Allavena.   

Abstract

Lymphocytes infiltrating human ovarian carcinoma obtained directly from the tumour mass (tumour-infiltrating lymphocytes, TIL) or from the carcinomatous ascites (tumour-associated lymphocytes, TAL) were expanded in vitro in long-term cultures with interleukin-2 and tested for their specific cytolytic activity. Killing of the autologous tumour was detected only in a proportion of the patients, less frequently in TIL compared to TAL. In fact two out of ten TIL and four out of nine TAL cultures tested showed significant levels of lysis against the autologous tumour. This cytotoxic activity was not restricted to the autologous tumour, as other tumour cell lines, including non-ovarian ones, were lysed as well. The cultures that were not cytotoxic against the autologous tumour were in most cases able to lyse other tumour cell lines of ovarian or other histology. Cloning of TIL from one patient was performed: of 22 clones tested, 4 displayed higher cytotoxicity against the autologous tumour compared to the uncloned population and 3 out of these 4 did not kill an irrelevant carcinoma cell line. In order to stimulate the expansion of putative specific effectors we performed mixed lymphocyte/tumour cultures (MLTC) with autologous or allogeneic tumour cells. No stimulation of cytotoxicity against the autologous tumour was detected after MLTC in nine different TAL populations, using autologous or allogeneic tumours as stimulators. On the contrary, peripheral blood lymphocytes from two patients after MLTC with the autologous tumour showed increased killing of the autologous and decreased killing of an allogeneic target. In conclusion TIL and TAL from ovarian carcinoma expanded in vitro with interleukin-2 usually have non-MHC-restricted cytotoxicity and variable degrees of reactivity against the autologous tumour. A preferential killing for the autologous tumour was not observed even after MLTC. These results do not exclude the existence of tumour-specific cytotoxic T lymphocytes in ovarian carcinoma; nevertheless they suggest that putative specific effectors have very low frequency and that culture techniques for expanding their growth more selectively are still to be optimized.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1387344     DOI: 10.1007/bf01789337

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  33 in total

Review 1.  Cellular immune response against autologous human malignant melanoma: are in vitro studies providing a framework for a more effective immunotherapy?

Authors:  G Parmiani; A Anichini; G Fossati
Journal:  J Natl Cancer Inst       Date:  1990-03-07       Impact factor: 13.506

2.  Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells.

Authors:  D L Barnd; M S Lan; R S Metzgar; O J Finn
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

3.  Preferential clonogenic deficit of CD8-positive T-lymphocytes infiltrating human solid tumors.

Authors:  S Miescher; M Stoeck; L Qiao; C Barras; L Barrelet; V von Fliedner
Journal:  Cancer Res       Date:  1988-12-15       Impact factor: 12.701

Review 4.  Activation of lymphocyte anti-tumour responses in man: effector heterogeneity and the search for immunomodulators.

Authors:  B M Vose
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

5.  Tumoricidal activity of macrophages isolated from human ascitic and solid ovarian carcinomas: augmentation by interferon, lymphokines and endotoxin.

Authors:  G Peri; N Polentarutti; C Sessa; C Mangioni; A Mantovani
Journal:  Int J Cancer       Date:  1981-08-15       Impact factor: 7.396

6.  Lymphocytes infiltrating human ovarian tumors. I. Role of Leu-19 (NKH1)-positive recombinant IL-2-activated cultures of lymphocytes infiltrating human ovarian tumors.

Authors:  D S Heo; T L Whiteside; A Kanbour; R B Herberman
Journal:  J Immunol       Date:  1988-06-01       Impact factor: 5.422

7.  Clonal analysis of T lymphocytes isolated from ovarian carcinoma ascitic fluid. Phenotypic and functional characterization of T-cell clones capable of lysing autologous carcinoma cells.

Authors:  S Ferrini; R Biassoni; A Moretta; M Bruzzone; A Nicolin; L Moretta
Journal:  Int J Cancer       Date:  1985-09-15       Impact factor: 7.396

8.  Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study.

Authors:  S L Topalian; D Solomon; F P Avis; A E Chang; D L Freerksen; W M Linehan; M T Lotze; C N Robertson; C A Seipp; P Simon
Journal:  J Clin Oncol       Date:  1988-05       Impact factor: 44.544

9.  Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity.

Authors:  A Belldegrun; L M Muul; S A Rosenberg
Journal:  Cancer Res       Date:  1988-01-01       Impact factor: 12.701

10.  Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor.

Authors:  K Itoh; C D Platsoucas; C M Balch
Journal:  J Exp Med       Date:  1988-10-01       Impact factor: 14.307

View more
  2 in total

1.  Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines.

Authors:  R P Negus; G W Stamp; J Hadley; F R Balkwill
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

2.  Clinical and biological effects of tumor-associated lymphocytes in the presence or absence of chemotherapy for malignant ascites in ovarian cancer patients.

Authors:  Weiwei Zhang; Kejun Liu; Bin Ye; Guolin Hu; Kelei Zhao; Yazhou Ren; Weijiang Liang
Journal:  Oncol Lett       Date:  2017-07-20       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.